Home > Insider Trading > Filing (0001062993-23-018279)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1042074	Cymabay Therapeutics Inc.	CBAY	Pharmaceutical Preparations (2834)	943103561

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1705745	Daniel Menold	C/O Cymabay Therapeutics, Inc. 7575 Gateway Blvd., Suite 110 Newark CA 94560	Vice President, Finance	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-09-15	1,545	$1.82	1,545	No	4	M	Direct
Common Stock	Disposition	2023-09-15	0	$16.87	0	No	4	S	Direct
Common Stock	Acquisiton	2023-09-15	15,000	$1.72	15,000	No	4	M	Direct
Common Stock	Disposition	2023-09-15	0	$16.87	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2023-09-15	1,545	$0.00	1,545	$1.82
Common Stock	Employee Stock Option (right to buy)	Disposition	2023-09-15	15,000	$0.00	15,000	$1.72

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2026-07-24	No	4	M	Direct
0		2027-01-18	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on April 10, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.44 to $17.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares subject to the option became vested and exercisable according to the following schedule: 25% of the shares subject to the option vested on July 22, 2017, and the remaining shares vested in equal monthly installments over the next 36 months.
The shares subject to the option became vested and exercisable according to the following schedule: 25% of the shares subject to the option vested on the first anniversary of the grant date, and the remaining shares vested in equal monthly installments over the next 36 months.